A phase III study for evaluation of immunogenicity and reactogenicity of Fluarix (Influsplit SSW)2007/2008 in people aged 18 years or above.
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2016
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 22 Mar 2012 Primary endpoints identified as reported by European Clinical Trials Database
- 07 Nov 2011 Actual initiation date (7 May 2007) added as reported by ClinicalTrials.gov.
- 16 Nov 2007 Status changed from in progress to completed.